Suppr超能文献

人乳头瘤病毒最新情况：疫苗接种、筛查及相关疾病

HPV Update: Vaccination, Screening, and Associated Disease.

作者信息

McNamara Megan, Batur Pelin, Walsh Judith M E, Johnson Kay M

机构信息

Department of Medicine, Case Western Reserve University School of Medicine and Louis Stokes Cleveland Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH, 44106, USA.

Department of Medicine and Primary Care Women's Health, Cleveland Clinic, Cleveland, OH, USA.

出版信息

J Gen Intern Med. 2016 Nov;31(11):1360-1366. doi: 10.1007/s11606-016-3725-z. Epub 2016 May 16.

DOI:10.1007/s11606-016-3725-z
PMID:27184752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5071275/
Abstract

Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening.

摘要

人乳头瘤病毒（HPV）感染是宫颈癌的致病因素，并且与包括外阴癌、阴道癌和肛门癌在内的许多其他生殖器癌症相关。HPV疫苗接种的一级预防是安全有效的，并且一种最近获批的HPV疫苗将提供针对几种致癌性HPV毒株的更广泛保护。HPV的筛查策略正在迅速发展，这反映了HPV感染在宫颈癌中所起的重要作用。本文重点介绍了有关最近获批的9价HPV（9vHPV）疫苗效力以及在宫颈癌筛查中使用一级高危HPV检测的新证据。我们考虑了尿液HPV检测在常规临床实践中的实用性，并回顾了有关肛门HPV筛查的现行指南。

相似文献

1
HPV Update: Vaccination, Screening, and Associated Disease.
J Gen Intern Med. 2016 Nov;31(11):1360-1366. doi: 10.1007/s11606-016-3725-z. Epub 2016 May 16.
2
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029.
3
Comprehensive control of human papillomavirus infections and related diseases.
Vaccine. 2013 Nov 22;31 Suppl 8(0 8):I1-31. doi: 10.1016/j.vaccine.2013.07.026.
4
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.
5
Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
J Clin Virol. 2016 Mar;76 Suppl 1(Suppl 1):S62-S68. doi: 10.1016/j.jcv.2015.11.020. Epub 2015 Nov 18.
6
Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
Expert Rev Anti Infect Ther. 2017 Nov;15(11):987-999. doi: 10.1080/14787210.2017.1392854. Epub 2017 Oct 20.
7
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
8
Comprehensive control of human papillomavirus infections and related diseases.
Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001.
9
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
BMC Infect Dis. 2021 Jan 6;21(1):11. doi: 10.1186/s12879-020-05632-0.
10
Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066.

引用本文的文献

1
The Impact of a Human Papillomavirus Facebook-Based Intervention (#HPVVaxTalks) Among Young Black (African American and Sub-Saharan African Immigrants) Adults: Pilot Pre- and Poststudy.
JMIR Form Res. 2025 Apr 2;9:e69609. doi: 10.2196/69609.
2
Decoding impact of human papillomavirus in gynecological oncology: a narrative review.
Obstet Gynecol Sci. 2025 Jan;68(1):30-42. doi: 10.5468/ogs.24226. Epub 2025 Jan 9.
3
A novel therapeutic multiepitope vaccine based on oncoprotein E6 and E7 of HPV 16 and 18: An approach.
Bioimpacts. 2024;14(5):27846. doi: 10.34172/bi.2024.27846. Epub 2024 Feb 6.
4
Longitudinal Screening for Oral High-Risk Non-HPV16 and Non-HPV18 Strains of Human Papillomavirus Reveals Increasing Prevalence among Adult and Pediatric Biorepository Samples: A Pilot Study.
Vaccines (Basel). 2024 Aug 8;12(8):895. doi: 10.3390/vaccines12080895.
5
Maternal HPV Infection: Effects on Pregnancy Outcome.
Viruses. 2021 Dec 7;13(12):2455. doi: 10.3390/v13122455.
6
Current update on vaginal malignancies.
Abdom Radiol (NY). 2021 Nov;46(11):5353-5368. doi: 10.1007/s00261-021-03228-z. Epub 2021 Aug 2.
7
Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.
Front Public Health. 2021 Jan 20;8:552028. doi: 10.3389/fpubh.2020.552028. eCollection 2020.
8
Cancer Prevention by Natural Products Introduced into the Diet-Selected Cyclitols.
Int J Mol Sci. 2020 Nov 26;21(23):8988. doi: 10.3390/ijms21238988.
9
Misinformation, Gendered Perceptions, and Low Healthcare Provider Communication Around HPV and the HPV Vaccine Among Young Sexual Minority Men in New York City: The P18 Cohort Study.
J Community Health. 2020 Aug;45(4):702-711. doi: 10.1007/s10900-019-00784-w.
10
Detection of precancerous lesions in the cervix and HPV infection in women in the region of Maniapure, Bolivar State.
Ecancermedicalscience. 2018 Dec 3;12:884. doi: 10.3332/ecancer.2018.884. eCollection 2018.

本文引用的文献

1
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
J Natl Cancer Inst. 2015 Oct 4;108(1). doi: 10.1093/jnci/djv282. Print 2016 Jan.
2
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.
MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):784-92. doi: 10.15585/mmwr.mm6429a3.
3
Sexually transmitted diseases treatment guidelines, 2015.
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.
4
Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
Ann Intern Med. 2015 Jun 16;162(12):851-9. doi: 10.7326/M14-2426.
5
Cervical cancer prevention: immunization and screening 2015.
Med Clin North Am. 2015 May;99(3):469-77. doi: 10.1016/j.mcna.2015.01.003. Epub 2015 Feb 28.
6
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4.
7
Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review.
Am J Obstet Gynecol. 2015 Sep;213(3):278-309. doi: 10.1016/j.ajog.2015.03.034. Epub 2015 Mar 19.
8
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.
9
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
Gynecol Oncol. 2015 Feb;136(2):189-97. doi: 10.1016/j.ygyno.2014.11.076. Epub 2015 Jan 8.
10
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
Obstet Gynecol. 2015 Feb;125(2):330-337. doi: 10.1097/AOG.0000000000000669.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验